Dengue green book chapter published

The dengue green book chapter has been published by the UK Health Security Agency on 15 October 2024 which includes the latest UK guidance on use of the dengue vaccine Qdenga®.

• see Dengue: the green book, chapter 15a

In the UK, the Qdenga® vaccine is currently recommended only for those with previous dengue infection. The objective is primarily to provide those who are at risk of dengue, and have already experienced dengue infection in the past, with protection from a secondary (and potentially more severe) infection.

Some key points from the guidance include:

• Qdenga® is the only licensed dengue vaccine available in the UK.
• It is a live attenuated vaccine for subcutaneous administration.
• Two doses should be given three months apart.
• Qdenga® vaccine can be considered for at risk individuals aged 4 years and over who have had dengue infection in the past.
• It is contraindicated for individuals less than 4 years of age, those who are pregnant, breastfeeding, immunocompromised (see Contraindications and special considerations: the green book, chapter 6) and those who have had a confirmed anaphylaxis reaction to a previous dose of the vaccine or any of the components of the vaccine.
• Tools are available (algorithm figure 1 and table 1) in the chapter to help assess if a traveller is a suitable candidate for Qdenga® vaccine.
• All suspected adverse reactions to Qdenga® should be reported on the yellow card scheme and to the manufacturers Takeda UK Ltd, email AE.GBR-IRL@takeda.com.
  

TRAVAX and fitfortravel dengue pages will reviewed and updated in due course to reflect the changes within the dengue chapter. A further news item will be published when these changes are complete.